Pertuzumab: tested in a combination
104 studies: another drug in the study is under test too. Page 1 of 2. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.
- HER2-positive Breast Cancer Without Intravenous Neoadjuvant TherapyNot yet recruitingNCT07848633Phase 2Report a problem
- Molecularly Tailored Therapy in Advanced Pancreatic CancerNot yet recruitingNCT07802418Phase 2Report a problem
- Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast CancerNot yet recruitingNCT07589972Not applicableReport a problem
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingNCT07565324Phase 2Report a problem
- Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.Enrolling by invitationNCT07550972Phase 2Report a problem
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingNCT07407920Phase 2Report a problem
- Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerRecruitingNCT07402473Phase 2Report a problem
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2Report a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingNCT07299890Phase 2Report a problem
- Identification of HER2-Positive Breast Cancer Molecular Characterization and SubtypesNot yet recruitingNCT07187752Not applicableReport a problem
- Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal CancerRecruitingNCT07108127Phase 2Report a problem
- Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Not applicableReport a problem
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabRecruitingNCT06876714Phase 3Report a problem
- Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast CancerNot yet recruitingNCT06578299Phase 4Report a problem
- The Sagittarius TrialRecruitingNCT06490536Phase 3Report a problem
- Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.RecruitingNCT06450314Phase 2Report a problem
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingNCT06441890Phase 2Report a problem
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2Report a problem
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingNCT06348134Phase 2Report a problem
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingNCT06162559Phase 1Report a problem
- A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BCRecruitingNCT05945368Phase 2Report a problem
- Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast CancerRecruitingNCT05891561Phase 2Report a problem
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/3Report a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3Report a problem
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2Report a problem
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2Report a problem
- TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal CancerRecruitingNCT05188313Phase 3Report a problem
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2Report a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingNCT04817956Phase 2Report a problem
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingNCT04680442Phase 2Report a problem
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2Report a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2Report a problem
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active, not recruitingNCT06136897Phase 2Results postedReport a problem
- Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedNCT05730712Phase 2Results postedReport a problem
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerCompletedNCT05415215Phase 3Results postedReport a problem
- A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery SystemCompletedNCT05275010Phase 1Results postedReport a problem
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results postedReport a problem
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerCompletedNCT04024462Phase 3Results postedReport a problem
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results postedReport a problem
- A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerCompletedNCT03493854Phase 3Results postedReport a problem
- S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT03365882Phase 2Results postedReport a problem
- Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast CancerActive, not recruitingNCT02827877Phase 2Results postedReport a problem
- Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.CompletedNCT02789657Phase 2Results postedReport a problem
- A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-RadiotherapyCompletedNCT02536339Phase 2Results postedReport a problem
- Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast CancerCompletedNCT02445586Phase 4Results postedReport a problem
- Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or BevacizumabActive, not recruitingNCT02436993Phase 2Results postedReport a problem
- Neoadjuvant Hormonal Therapy Combined With ChemoimmunotherapyTerminatedNCT02345772Phase 1/2Results postedReport a problem
- T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingNCT02326974Phase 2Results postedReport a problem
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results postedReport a problem
- Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based TherapyCompletedNCT02252887Phase 2Results postedReport a problem
- Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast CancerCompletedNCT02139358Phase 1/2Results postedReport a problem
- A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast CancerCompletedNCT02132949Phase 2Results postedReport a problem
- My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results postedReport a problem
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.TerminatedNCT02000596Phase 2Results postedReport a problem
- Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast CancerCompletedNCT01959490Phase 2Results postedReport a problem
- Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast CancerActive, not recruitingNCT01937117Phase 2Results postedReport a problem
- Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerTerminatedNCT01912963Phase 2Results postedReport a problem
- Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast CancerCompletedNCT01855828Phase 2Results postedReport a problem
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCaCompletedNCT01796197Phase 2Results postedReport a problem
- Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast CancerCompletedNCT01730833Phase 2Results postedReport a problem
- Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)CompletedNCT01684878Phase 3Results postedReport a problem
- A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerCompletedNCT01565083Phase 2Results postedReport a problem
- A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)CompletedNCT01120184Phase 3Results postedReport a problem
- Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast CancerCompletedNCT01048099Not applicableResults postedReport a problem
- A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received TrastuzumabCompletedNCT00875979Phase 1/2Results postedReport a problem
- A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.CompletedNCT00545688Phase 2Results postedReport a problem
- Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast CancerCompletedNCT07115095Not applicableReport a problem
- Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical PracticeCompletedNCT06907082Not applicableReport a problem
- PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerActive, not recruitingNCT06172127Phase 2Report a problem
- Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeActive, not recruitingNCT06068985Phase 2Report a problem
- Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCCompletedNCT05969184Phase 2Report a problem
- Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast CancerStatus unknownNCT05749016Phase 2Report a problem
- STOP-HER2: Stopping Trastuzumab in HER2+ MBCActive, not recruitingNCT05721248Phase 2Report a problem
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3Report a problem
- PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast CancerStatus unknownNCT05346107Phase 2Report a problem
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingNCT05256225Phase 3Report a problem
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1Report a problem
- Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2Report a problem
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active, not recruitingNCT04784715Phase 3Report a problem
- Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruitingNCT04733118Phase 2Report a problem
- De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeTerminatedNCT04675827Phase 2Report a problem
- Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal DiseaseActive, not recruitingNCT04588545Phase 1/2Report a problem
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerActive, not recruitingNCT04569747Phase 2Report a problem
- CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2Report a problem
- Her2-positive Lung Cancer Treated With Dedicated DrugCompletedNCT03845270Phase 2Report a problem
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingNCT03803553Phase 3Report a problem
- DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCActive, not recruitingNCT03716180Phase 1Report a problem
- Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingStatus unknownNCT03412643Phase 2Report a problem
- Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive, not recruitingNCT03304080Phase 1/2Report a problem
- Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2Report a problem
- Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.Active, not recruitingNCT03161353Phase 2Report a problem
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerStatus unknownNCT02689921Phase 2Report a problem
- PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive, not recruitingNCT02624973Phase 2Report a problem
- Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast CancerTerminatedNCT02598427Phase 1Report a problem
- FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ CancerCompletedNCT02581462Phase 2/3Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2Report a problem
- Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal TherapyCompletedNCT02411344Phase 2Report a problem
- Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02205047Phase 2Report a problem